Tablets 7,5 mg
Tablets 15 mg

ATC  M01A C06
Prescription-only medicine


Oral use.

The total daily amount should be taken as a single dose, with water or another liquid, during a meal.

Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms. The patient’s need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis.

Exacerbations of osteoarthrosis: 7.5 mg/day. If necessary, the dose may be increased to 15 mg/day.

Rheumatoid arthritis, ankylosing spondylitis: 15 mg/day. According to the therapeutic response, the dose may be reduced to 7.5 mg/day.


Special populations

Elderly Patient and Patients with Increased Risk of Adverse Reaction

The recommended dose for long term treatment of rheumatoid arthritis and ankylosing spondylitis in elderly patients is 7.5 mg per day. Patients with increased risks for adverse reactions should start treatment with 7.5 mg per day.

Patients with Renal Impairment

In dialysis patients with severe renal failure, the dose of meloxicam should not exceed 7.5 mg per day. No dose reduction is required in patients with mild to moderate renal impairment (i.e. patients with a creatinine clearance of greater than 25 ml/min).

Patients with Hepatic Impairment

No dose reduction is required in patients with mild to moderate hepatic impairment.

Children and Adolescents

Meloxicam tablets are contraindicated in children and adolescents aged under 16 years.

Medicine’s information on this web page is only a short description of its characteristics. Do not take them as recommendations for self-treatment of your health condition.

You must inform your physician and pharmacist and follow their recommendations before you use the medicine for treatment. Always read carefully the patient information leaflet.


Each tablet contains 7.5 mg meloxicam, excipients.
Each tablet contains 15 mg meloxicam, excipients.


Meloxicam is indicated for: - short-term symptomatic treatment of exacerbations of osteoarthrosis, - long-term symptomatic treatment of rheumatoid arthritis or ankylosing spondylitis.


Meloxicam is contra-indicated in the following situations:
– third trimester of pregnancy;
– children and adolescents aged under 16 years;
– hypersensitivity to meloxicam or to any of the excipients or hypersensitivity to substances with a similar action, e.g. acetylsalicylic acid and nonsteroidal anti-inflammatory drugs (NSAIDs). Meloxicam should not be given to patients who have developed signs of asthma, nasal polyps, angioneurotic edema or urticaria following the administration of acetylsalicylic acid or other NSAIDs;
– history of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy;
– active, or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding);
– severely impaired liver function;
– non-dialysed severe renal failure;
– gastrointestinal bleeding, history of cerebrovascular bleeding or other bleeding disorders;
– severe heart failure.


Box with 20 tablets of 7.5 mg (2 blisters x 10 tablets).
Box with 20 tablets of 15 mg (2 blisters x 10 tablets).